Streetbeat News

Revenues

ABBV

In the last three months, 7 analysts have updated their ratings on AbbVie (NYSE:ABBV), showing a positive trend with 2 bullish and 5 somewhat bullish ratings. The average 12-month price target for ABBV has been raised to $188.29, indicating a 4.44% increase from the previous target. Analysts from firms like Guggenheim, Raymond James, and Barclays have raised their price targets, reflecting optimism about AbbVie's future performance despite recent challenges in revenue growth and profitability metrics.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 7:01 pm

ABSI

Six analysts have recently assessed Absci (NASDAQ:ABSI), showing a mix of bullish and somewhat bullish ratings with an average 12-month price target of $8.17, a significant increase from the previous $4.00. Absci, an AI-powered synthetic biology company, has seen a revenue decline of -68.59% over the past 3 months, with a net margin of -2956.18%, ROE of -10.68%, and ROA of -8.97%. Despite the financial challenges, the company's market position remains strong with a low debt-to-equity ratio of 0.09.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 7:01 pm

FDS

FactSet Research Systems (NYSE:FDS) received mixed analyst ratings with 3 indifferent and 1 bearish over the past three months. The average 12-month price target is $453.0, reflecting a 5.72% increase from the previous $428.50. Analyst actions include maintaining, raising, and lowering ratings with price targets adjusted accordingly. FactSet's financial performance shows positive revenue growth, high net margin, ROE, and ROA, but faces challenges in market capitalization and debt management.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 7:00 pm

VALN

Valneva (NASDAQ:VALN) received mixed analyst ratings, with a recent shift towards a bullish outlook. The average 12-month price target is $23.75, marking a 31.94% increase from the previous target. Despite facing a significant revenue decline of -75.7% as of September 30, 2023, and challenges in revenue growth and ROE, Valneva's net margin and ROA outperform industry standards. The company's debt-to-equity ratio is higher than the industry average, indicating a reliance on borrowed funds.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 6:01 pm

RJF

Analyst ratings for Raymond James Finl (NYSE:RJF) show a mix of sentiments, with recent updates indicating a generally neutral to positive outlook. The 12-month price targets suggest an upward trend, with the current average target at $120.5, marking an 8.48% increase from the previous average of $111.08. Raymond James Financial, a major financial holding company, has shown impressive financial performance with significant revenue growth, high net margin, and strong ROE and ROA, despite a lower growth rate compared to its peers.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 6:00 pm

CHX

OIH

PXJ

ChampionX Corporation (NASDAQ:CHX) announced its plan to acquire RMSpumptools Limited for approximately $110 million, aiming to strengthen its global presence in artificial lift solutions. The acquisition, expected to close by Q3 2024, is anticipated to generate around $65 million in revenues and $18 million in adjusted EBITDA for 2024. This move aligns with ChampionX's strategy for technology acquisitions and is funded by cash on hand, without affecting its 2024 capital return framework. CHX stock has seen over a 35% increase in the past year.

Portfolio Pulse from Nabaparna Bhattacharya

March 22, 2024 | 5:17 pm

APEI

Analysts have varied opinions on American Public Education (NASDAQ:APEI), with recent ratings ranging from bullish to bearish. The average 12-month price target is $14.00, marking a 36.59% increase from the previous target of $10.25. Financial indicators show positive revenue growth, high net margin, and strong ROE and ROA, but a high debt-to-equity ratio. The company offers postsecondary education and has seen a revenue growth rate of 0.24% as of December 31, 2023.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 5:01 pm

LPLA

Analysts have diverse views on LPL Financial Holdings (LPLA), with recent evaluations showing a mix of indifference and slight bullishness. The average 12-month price target for LPLA has been raised to $266.57, indicating a positive outlook. The company has shown strong financial performance with a notable revenue growth rate of 13.31% and excels in ROE and ROA, despite a below-average net margin and market capitalization.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 5:01 pm

EPAM

18 analysts have recently updated their ratings and price targets for EPAM Systems (NYSE:EPAM), showing a mix of bullish and bearish perspectives. The average 12-month price target is now $326.67, up from $293.38, indicating a positive sentiment shift. Analyst actions include maintaining, raising, and lowering ratings, reflecting responses to market dynamics and EPAM's performance. Despite a challenging quarter with a revenue decline of -6.01% and below-average net margin and ROE, EPAM's strong ROA and low debt-to-equity ratio highlight its financial health.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 5:00 pm

SF

Analysts have provided diverse opinions on Stifel Financial (NYSE:SF) over the last three months, with recent ratings ranging from somewhat bullish to indifferent. The average 12-month price target for SF has increased by 10.22% to $81.75. Key financial indicators show solid revenue growth and net margin, but challenges in ROA and market capitalization. Stifel Financial is a middle-market-focused investment bank with significant revenue from its global wealth management division.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 5:00 pm